NCT06726863 - Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 22, 2024

Primary Completion Date

January 27, 2025

Study Completion Date

February 1, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

Vamifeport IRF

Vamifeport IRF will be administered orally as per the dosing levels and formulations for respective treatment periods.

DRUG

Vamifeport PR1

Vamifeport PR1 will be administered orally as per the dosing levels and formulations for respective treatment periods.

DRUG

Vamifeport PR2

Vamifeport PR2 will be administered orally as per the dosing levels and formulations for respective treatment periods.

Trial Locations (1)

Investigator Site 82600083, Leeds